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Abstract
Background Ursodeoxycholic acid (UDCA) remains the first-line therapy for primary biliary cholangitis (PBC); however,
inadequate treatment response (ITR) is common. The UK-PBC Consortium developed the modified UDCA Response Score
(m-URS) to predict ITR (using alkaline phosphatase [ALP] > 1.67 times the upper limit of normal [*ULN]) at 12 months
post-UDCA initiation). Using data from the US-based Fibrotic Liver Disease Consortium, we assessed the m-URS in our
multi-racial cohort. We then used a dynamic modeling approach to improve prediction accuracy.
Methods Using data collected at the time of UDCA initiation, we assessed the m-URS using the original formula; then, by
calibrating coefficients to our data, we also assessed whether it remained accurate when using Paris II criteria for ITR. Next,
we developed and validated a dynamic risk prediction model that included post-UDCA initiation laboratory data.
Results Among 1578 patients (13% men; 8% African American, 9% Asian American/American Indian/Pacific Islander; 25%
Hispanic), the rate of ITR was 27% using ALP > 1.67*ULN and 45% using Paris II criteria. M-URS accuracy was “very
good” (AUROC = 0.87, sensitivity = 0.62, and specificity = 0.82) for ALP > 1.67*ULN and “moderate” (AUROC = 0.74,
sensitivity = 0.57, and specificity = 0.70) for Paris II. Our dynamic model significantly improved accuracy for both definitions
of ITR (ALP > 1.67*ULN: AUROC = 0.91; Paris II: AUROC = 0.81); specificity approached 100%. Roughly 9% of patients
in our cohort were at the highest risk of ITR.
Conclusions Early identification of patients who will not respond to UDCA treatment using a dynamic prediction model
based on longitudinal, repeated risk factor measurements may facilitate earlier introduction of adjuvant treatment.
Keywords Primary biliary cirrhosis · Alkaline phosphatase · Paris II

Introduction
Ursodeoxycholic acid (UDCA) is the primary first-line treatment for primary biliary cholangitis (PBC), but an estimated
4 in 10 PBC patients fail to respond adequately to t herapy1.
Inadequate treatment response (ITR)—generally defined
as a lack of improvement in liver laboratory parameters at
12 months after treatment initiation2—leaves patients at
risk of progressive liver disease, including decompensated
Dr. Li accepts full responsibility for the conduct of the study.
* Jia Li
jli4@hfhs.org
Extended author information available on the last page of the article

cirrhosis and liver transplant. However, use of this 12-month
timeline means that patients who will ultimately require
second-line therapies must wait at least a year prior to their
initiation. Early and more robust identification of patients
unlikely to benefit from UDCA would allow clinicians to
target introduction of adjuvant or alternative therapies earlier in the disease process, when successful treatment might
mitigate liver disease progression.
Several studies have identified factors that predict likelihood of ITR, including younger age at diagnosis, longer
time between diagnosis and treatment initiation, as well as
laboratory parameters such as alkaline phosphatase (ALP)3,
4
. A recent predictive model—the UDCA Response Score
(URS)—developed by the UK-PBC Consortium demonstrated “good” accuracy (area under the receiver operator
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characteristic curve [AUROC] = 0.83) when ITR was defined
as ALP > 1.67 times the upper limit of normal (*ULN) at
12 months after UDCA initiation.3 However, this cohort was
limited to PBC patients with completed laboratory assessments at two time points (time of PBC diagnosis and time
of UDCA initiation), which is not always feasible in “real
world” patients. Accuracy of a version of this model adapted
to use variables collected at a single time point—the modified URS (m-URS)—was slightly reduced (AUROC = 0.81
95% CI 0.77–0.84). Another group developed a model predicting UDCA response, using a cohort of PBC patients
from Beijing, China; model accuracy was similar to the UKPBC model (AUROC = 0.80, 95% CI: 0.68–0.89).4
The Fibrotic Liver Disease (FOLD) Consortium recently
showed that, in contrast to the perception of PBC as a disease of White women in late middle age, significant proportions of this US-based cohort were Hispanic, African American, or Asian American/American Indian/Pacific Islanders
(ASINPI). Given racial differences in PBC prevalence and
benefits of UDCA t reatment5–7, it is not clear that the abovementioned European and Chinese results are generalizable
to a US cohort. Likewise, previous studies have documented
geographic differences in PBC prevalence, suggesting possible differences in exposure to some yet-undefined risk
factor(s) that could influence response to U
 DCA8. Therefore, we had three goals for this analysis: First, we sought
to validate the m-URS3 among a racially and geographically diverse US cohort. Second, we also evaluated whether
the m-URS could be improved with additional calibration
(adjustment of coefficients). Finally, we used machine-learning methods to explore a new predictive model (optimized
based on accuracy, parsimony, and duration from treatment initiation) that would increase predictive ability and
accurately classify patients at the highest risk of ITR. This
resulted in the development of a dynamic ITR risk prediction model using longitudinal measurements of post-baseline
biomarkers that included of laboratory measures in the first
months after UDCA treatment initiation.

Methods
The FOLD Consortium has been previously described.5, 6
Briefly, FOLD comprises 11 geographically diverse health
systems, representing four US Census Bureau-defined
regions (Northeast, Midwest, Northwest, and South).
FOLD follows the guidelines of the US Department of
Health and Human Services for the protection of human
subjects. The study protocol was approved by the Institutional Review Board of each participating site. The
requirement for written informed consent was waived due
to the observational and de-identified nature of the data.
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Patient Cohort
FOLD PBC patient identification methods have been previously described.6 Our PBC cohort was identified using
an automated Classification and Regression Tree (CART)
algorithm. Patients were classified as having PBC if they
met one of three conditions: 1) AMA-positive with at
least one PBC diagnosis code; 2) AMA-positive with
ALP > 150 (in the absence of a PBC diagnosis code); or
3) presence of two PBC diagnosis codes (in the absence
of an AMA-positive result). Classification accuracy was
excellent: AUROC = 93.4%, sensitivity 93.4%, specificity
86.5%, PPV 79.2%, and NPV 96.8%. Application of the
CART algorithm to the preliminary patient pool identified
4,241 “true” PBC cases. Of these, 1645 had an AMA-positive test and one or more PBC diagnosis codes; 832 had
an AMA-positive test and ALP > 150; and 1764 patients
presented with two or more PBC diagnosis codes. These
categories were mutually exclusive. All cases were confirmed with chart abstraction performed by trained medical
abstractors; FOLD hepatologists provided adjudication of
indeterminate cases.
PBC patients that initiated UDCA treatment between
January 1, 2006 and December 31, 2016 and had at least
12 months of follow-up data after UDCA initiation were
included in this analysis. We excluded patients with a history of UDCA treatment prior to 2006 and those without at
least one of three laboratory results for calculation of Paris II
criteria2 (ALP, aspartate aminotransferase [AST], and total
bilirubin) 12 months after treatment initiation. For validation
of the m-URS, data were randomly divided into a training
dataset and a validation dataset using a 2:1 ratio.

Covariates
“Index date” was defined as the date of UDCA treatment
initiation. Variables collected at index date included patient
demographics (gender, race/ethnicity, age) and the following laboratory parameters: bilirubin; ALP in relation to the
upper limit of normal (ULN) defined by the assay used at
each site; albumin (again in relation to the site-defined “normal”); ratio of AST to alanine aminotransferase (ALT) 9;
AST to Platelet Ratio Index (APRI); and Fibrosis 4 Index
(FIB4; a biomarker comprising age, ALT, AST, and platelet counts). For the dynamic parameters, ALP, AST, ALT,
bilirubin, and albumin were summarized using a median
smoother in monthly intervals, up to 7 months from the
index date.
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Outcomes
We assessed the accuracy of prediction models using two
established criteria: 1) Toronto criteria (ALP > 1.67*ULN
at 12 months post-UDCA initiation), as used by the modified UDCA Response Score (m-URS); and 2) Paris II
criteria2 (any of the following: total bilirubin > 1 mg/dL;
AST ≥ 1.5*ULN; or ALP ≥ 1.5*ULN, based on the first laboratory results ≥ 12 months after UDCA treatment initiation).

Statistical Analysis
In order to validate and recalibrate the m-URS, data were
randomly divided into a training dataset and a validation
dataset using a 2:1 ratio. The m-URS includes four variables
measured at the time of UDCA treatment initiation (age; 1/
√total bilirubin; logALT; and logALP), calculated with a logit
model; ITR is defined as ALP > 1.67*ULN at 12 months
post-treatment initiation. We validated the model several
ways: 1) by applying the m-URS variables/coefficients and
main outcome (ALP > 1.67*ULN) directly to our validation
data set; 2) by calibrating the coefficients of m-URS variables based on our training data using logistic regression,
and testing these refined coefficients using the validation
data. Model accuracy was assessed for ITR defined by both
ALP > 1.67*ULN or Paris II criteria. Multiple imputation
was used to address missing laboratory data at baseline.
Next, we sought to determine whether the inclusion of
dynamic longitudinal laboratory measures obtained after
treatment initiation improved prediction of ITR by performed a two-step analysis based on information derived
from each patient’s individual trajectory of laboratory markers. First, a linear regression analysis was performed with
“time from treatment initiation” as the independent variable
and repeated measurements of ALP as the dependent variable. This analysis was performed separately for each patient,
using data from baseline up to 7 months post-index, in order
to obtain subject-specific growth curves over this time interval. In addition to a linear growth curve, we also applied
quadratic and piecewise functions; the final function for the
selected growth curve was chosen based on goodness-of-fit.
Similar strategies were used with other laboratory markers
(AST, ALT, total bilirubin). Next, each patients’ baseline
characteristics and their patient-specific growth parameters
(i.e., slope coefficient[s]) were entered into a logistic model
to predict ITR at 12 months after treatment initiation, generating an individual “risk score.” Dynamic risk prediction
models were developed separately for the ALP > 1.67*ULN
and Paris II criteria for ITR. Training data were used to build
this dynamic risk prediction model.
Model selection was based on balancing model predictive
ability and complexity. Model parameters such as number of
covariates and number of time intervals to calculate growth

parameters were evaluated by tenfold cross-validation on the
training data. Predictive ability of the models was further
assessed at baseline and each month post-treatment initiation
on the validation data. Model prediction accuracy for both
m-URS and our dynamic model was assessed by receiver
operating characteristic curves (ROC) and the precisionrecall curve (PRC) as an alternative metric, which is preferable when outcomes are imbalanced. Confidence intervals and comparisons between models for area under ROC
(AUROC) and area under PRC (AUPRC) were estimated by
1,000 bootstraps. Other metrics such as sensitivity, specificity, positive predictive value (PPV), and negative predictive
value (NPV) were used to calculate a cutoff value for the risk
score. The cutoff point for this score was derived by optimizing the PPV. This model was developed using imputed data.
We further conducted two sensitivity analyses. First,
the model was tested on a subset of the validation data that
excluded patients with missing baseline laboratory measurements. Second, the model was tested on the subset of
patients in validation data who had data from at least one set
of post-treatment laboratory measures.

Results
Table 1 displays the twelve baseline variables considered in
the univariate analysis, including imputed values, by UDCA
response status. We identified 1578 patients who initiated
UDCA treatment during the study period: 8% were African
American; 9% were ASINPI; 67% were White; and 25%
were Hispanic of any race. Thirteen percent were men. A
total of 419 (27%) demonstrated ITR at 12 months from
index using ALP > 1.67*ULN, whereas 706 (45%) had ITR
using Paris II criteria. Values were missing for 6–23% of
baseline covariates; multiple imputation was used to estimate these missing values.

Validation of the Modified UDCA Response Score
(m‑URS)
Among a total of 1578 patients (1052 in the training data
and 526 in the validation data), baseline measurements were
available for 1270 patients. After imputation to address
missing data, the AUROC of the m-URS based on baseline
covariates was 0.89 (95% CI 0.86–0.92) and the AUPRC was
0.69 (95% CI 0.60–0.79); Table 2) in the validation dataset.
Using the m-URS variables but allowing the coefficients
to vary yielded similar predictive ability (see formula in
Supplemental Table 1), the AUROC for the model for predicting ITR defined as ALP > 1.67*ULN was 0.89 (95% CI
0.86–0.92); the AUPRC was 0.69 (95% CI 0.61–0.78). Using
Paris II criteria as the outcome of interest, application of the
m-URS yielded an AUROC of 0.76 (95% CI 0.72–0.80),
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Table 1  Univariate analysis of baseline variables for the full sample
(A), for the full sample with unknown values imputed (B), and by
response to UDCA treatment at 12 months after initiation of therapy
Variable
US Census Region

Gender
Race

Hispanic

Age

Albumin

Alkaline phosphatase

Response

(C and D) defined by alkaline phosphatase (< 1.67 times the upper
limit of normal) at 12 months post-treatment initiation

A. All

B. All with imputation

C. Responder

D. Non-responder

(N = 1578)

(N = 1578)

(N = 872)

(N = 706)

Midwest

308 (20%)

308 (20%)

163 (19%)

145 (21%)

Northeast

99 (6%)

99 (6%)

69 (8%)

30 (4%)

South

157 (10%)

157 (10%)

96 (11%)

61 (9%)

West

1014 (64%)

1014 (64%)

544 (62%)

470 (67%)

Women

1371 (87%)

1371 (87%)

768 (88%)

603 (85%)

Men

207 (13%)

207 (13%)

104 (12%)

103 (15%)

AS/IN/PI

137 (9%)

151 (10%)

88 (10%)

63 (9%)

Black

126 (8%)

139 (9%)

70 (8%)

69 (10%)

White

1057 (67%)

1288 (82%)

714 (82%)

574 (81%)

Missing

258 (16%)

Yes

392 (25%)

412 (26%)

211 (24%)

201 (28%)

No

1088 (69%)

1166 (74%)

661 (76%)

505 (72%)

Missing

98 (6%)

≤ 40

123 (8%)

123 (8%)

59 (7%)

64 (9%)

41‒50

283 (18%)

283 (18%)

143 (16%)

140 (20%)

51‒60

496 (31%)

496 (31%)

280 (32%)

216 (31%)

61‒70

428 (27%)

428 (27%)

237 (27%)

191 (27%)

> 70

248 (16%)

248 (16%)

153 (18%)

95 (13%)

< LLN

328 (21%)

385 (24%)

150 (17%)

235 (33%)

Normal

887 (56%)

1193 (76%)

722 (83%)

471 (67%)

Missing

363 (23%)

< ULN

280 (18%)

424 (27%)

119 (17%)

305 (35%)

[1,1.5)*ULN

345 (22%)

345 (22%)

98 (14%)

247 (28%)

[1.5,2)*ULN

248 (16%)

248 (16%)

101 (14%)

147 (17%)

[2,3)*ULN

263 (17%)

263 (17%)

154 (22%)

109 (13%)

≥ 3*ULN

298 (19%)

298 (19%)

234 (33%)

64 (7%)

Missing

144 (9%)

Bilirubin (mg/dL)

> 2.0

116 (7%)

127 (8%)

25 (3%)

102 (14%)

ALT

2.0 > 1.5

64 (4%)

103 (7%)

37 (4%)

66 (9%)

1.5 > 1.0

131 (8%)

144 (9%)

54 (6%)

90 (13%)

1.0 > 0.7

252 (16%)

317 (20%)

152 (17%)

165 (23%)

0.7 > 0.5

254 (16%)

283 (18%)

163 (19%)

120 (17%)

0.5 > 0.4

163 (10%)

192 (12%)

133 (15%)

59 (8%)

≤ 0.4

349 (22%)

412 (26%)

308 (35%)

104 (15%)

Missing

249 (16%)

Platelets

AST/ALT ≥1.1

APRI Score

FIB4 Index

Normal

1084 (69%)

1240 (79%)

743 (85%)

497 (70%)

< LLN

311 (20%)

338 (21%)

129 (15%)

209 (30%)

Missing

183 (12%)

Yes

451 (29%)

464 (29%)

217 (25%)

247 (35%)

No

919 (58%)

1114 (71%)

655 (75%)

459 (65%)

Missing

208 (13%)

N

1213

1578

872

706

Mean (SD)

1.8 (4.93)

1.7 (4.99)

1.5 (5.66)

2.0 (4.00)

Median

0.73

0.77

0.57

1.09

N

1207

1578

872

706

Mean (SD)

10.7 (36.92)

10.5 (37.11)

8.5 (27.49)

12.9 (46.22)

Median

1.95

2.06

1.75

2.62

P value
0.006

0.119
0.382

0.055

0.047

< .001

< .001

< .001

< .001

< .001

0.022

0.029

AS/IN/PI: Asian American, American Indian, Pacific Islander; ULN: upper limit of normal, as defined by the assay used at each site; LLN:
lower limit of normal, as defined by the assay used at each site; AST/ALT: ratio of aspartate aminotransferase to alanine aminotransferase (≥ 1.1
indicates cirrhosis); APRI: Aspartate aminotransferase to Platelet Ratio Index; SD: standard deviation; FIB4: Fibrosis 4; UDCA: ursodeoxycholic acid
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Table 2  Assessment of the performance of the modified UDCA
Response Score (m-URS) to predict inadequate treatment response
(ITR) at 12 months post-treatment initiation in patients from the

Fibrotic Liver Disease (FOLD) cohort. Missing baseline data were
imputed by multiple imputation

ITR Criteria

Model

AUROC (95% CI)

AUPRC (95% CI)

ALP > 1.67*ULN

Original (full cohort)
Original (validation)
Recalibrated (validation)
Original (full cohort)
Original (validation)
Recalibrated (validation)

0.87 (0.85,0.89)
0.89 (0.86, 0.92)
0.89 (0.86, 0.92)
0.77 (0.74, 0.79)
0.76 (0.72,0.80)
0.79 (0.76, 0.83)

0.71 (0.66,0.76)
0.69 (0.60, 0.79)
0.69 (0.61, 0.78)
0.74 (0.70, 0.77)
0.74 (0.68, 0.79)
0.75 (0.70,0.82)

Paris II

ITR Inadequate treatment response, AUROC Area under the receiver operating curve, AUPRC Area under the precision-recall curve

and an AUPRC of 0.74 (95% CI 0.68–0.79). When the coefficients of m-URS were recalibrated, AUROC was 0.79 (95%
CI 0.76–0.83), and AUPRC was 0.75 (95% CI 0.70–0.82).
We also performed a separate sensitivity analysis using
m-URS variables/coefficients, but including an “unknown”
category for covariates with missing (see Table 1 Column
A). This demonstrated lower predictive ability (AUROC
0.72, 95% CI 0.68–0.77 using validation data).

Improvement of ITR Prediction Using Dynamic Risk
Prediction
During model development, we observed a biphasic evolution of laboratory markers over time after treatment initiation. To address this, a piecewise linear spline model was
fitted with “time from treatment” as the predictor and ALP
as the outcome. This method was used to estimate changes
in the longitudinal pattern of each laboratory marker,
with one slope representing the change ≤ 2 months posttreatment initiation and the second slope presenting the
change > 2 months of treatment initiation. The final logistic
model included gender, age, and baseline measurements of
ALP, AST, ALT, and bilirubin, and their growth parameters
after treatment initiation. The formula for the dynamic predictive score of ITR for each patient is provided in Supplemental Table 1S.
In order to validate the dynamic prediction model at
each follow-up time point, the growth curve estimates were
updated monthly if additional ALP data became available; if
no additional measurement of ALP was available, the slope
derived from the previous measure was used. Similar strategies were used with other laboratory markers. Model predictive ability (Fig. 1a) was consistently better than the recalibrated m-URS over time; there were significantly improved
(p value < 0.05) starting at month 4 (AUROC 0.91, 95% CI
0.88–0.94) compared to m-URS (0.89, 95% CI 0.86–0.92).
Similarly, AUPRC of the dynamic model was significantly
better than the m-URS beginning at month 4 (0.74, 95%
CI 0.64–0.82, versus 0.69, 95% CI 0.60–0.78, respectively).

Predictive accuracy of the dynamic model improved over
time as more measurements became available. At month 7,
AUROC was 0.91 (95% CI 0.89–0.94) and AUPRC was 0.77
(95% CI 0.68–0.85). Both were significantly higher than the
m-URS (p values < 0.01). Figure 2a shows additional metrics at each time point based on the cut-points optimized by
PPV. Patients with risk scores > 0.84 were considered to be
at the highest risk of ITR. Using this cut-point, the model
showed that roughly 9% of patients in our cohort were in
the highest risk group for ITR. At baseline, the model classified 74 of the 525 available patients (14%) into the highrisk group, of whom 53 of these patients ultimately had ITR
(ALP > 1.67*ULN), for a PPV of 71.6%. At 7 months posttreatment initiation, the model classified 52 patients (9.9%)
as high risk, of whom 44 had ITR (ALP > 1.67*ULN); the
PPV was significantly improved to 84.6%. Specificity was
improved from 95% at baseline to 98% at month 4 and was
consistent afterward; NPV remained stable at 83%.
For the first sensitivity analysis, we excluded patients in
the validation cohort with missing baseline data (n = 414).
At month 4, the AUROC of our dynamic risk prediction
model became significantly higher than m-URS (Supplemental Fig. 1; 0.90; 95% CI: 0.87–0.94; p = 0.034); the
AUPRC became significantly higher than the m-URS at
month 3 (0.74, 95% CI 0.65–0.84; p = 0.05). Results were
also consistent when we excluded patients without posttreatment laboratory data (n = 347; Supplemental Fig. 2).
Figures 3a and b illustrate how our dynamic modeling
facilitates accurate and personalized prediction rules for ITR
(ALP > 1.67*ULN at 12 months post-treatment initiation)
using four select patients. For patient A, predicted risk for
ITR was low at treatment initiation (ITR risk: 0.06, 95% CI
0.04–0.08) and generally remained low across the 6-month
observation (ITR risk: 0.07; 95% CI 0.04–0.09). Patient
B appeared to have only moderate risk of ITR at baseline
(0.74, 95% CI 0.68–0.74), but estimated risk increased as
more laboratory data became available. At 6 months posttreatment initiation, patient B passed into “high risk” threshold (0.84) for ITR (0.86; 95% CI 0.81–0.91). For patient
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Fig. 1  Comparison of predictive ability between our dynamic model
and the m-URS, using area under the ROC curves (AUROC) and
area under the PR curves (AUPRC) based on data for up to 7 months
after initiation of ursodeoxycholic acid treatment, using two criteria:

13

a Alkaline phosphatase (ALP) > 1.67 times the upper limit of normal (ULN) and b Paris II criteria. Patients with missing baseline data
were imputed (n = 525 for validation data)

Digestive Diseases and Sciences

Fig. 2  Prediction metrics for predicting ITR to ursodeoxycholic acid
at each time point after treatment initiation, using the dynamic risk
prediction model, using a: alkaline phosphatase (ALP) > 1.67 times
the upper limit of normal at 12 months after treatment initiation; and
b Paris II criteria. Sensitivity, specificity, PPV, and NPV were cal-

culated based on cutoff of 0.84. Patients with missing baseline data
were imputed (n = 525 for validation data). ITR Inadequate treatment
response, AUROC Area under the receiver operating curve, AUPRC
Area under the precision-recall curve, PPV positive predictive value,
NPV negative predictive value
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(a)

17
16

ALP in rela

n to the upper limit of normal

15
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9

A

8

B

7

C

6

D

5
4
3
2

Discussion

1
0
0

1

2

3

4

5

6

Month post treatment in a on

(b)
1

Predicted probability of ITR

Next, using the Paris II criteria to define ITR, we developed a dynamic model (Table S1) based on gender, age
and repeated measures of ALP and bilirubin. AUROC and
AUPRC at baseline were 0.79 (95% CI 0.75–0.83) and 0.75
(95% CI 0.69–0.81), respectively (Fig. 1b). The AUROC was
significantly higher than the recalibrated m-URS starting
in month 3, which was stable at 0.82 (95% CI: 0.79–0.86)
beginning at 4 months post-treatment; the AUPRC was significantly higher than the value of m-URS from month 2
(0.79; 95% CI, 0.73–0.84). With a cut-point of 0.84, the
model determined that roughly 30% of patients in our cohort
would be considered to have the highest risk of ITR. PPV
remained high for predicting ITR, ranging from 83.0% at
baseline to 92.3% at 7 months post-treatment; corresponding
specificities ranged from 94.4% to 98.3% (Fig. 2b).

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0

2

3

4

5

6

Month post treatment in a on

Fig. 3  Repeated measurement of alkaline phosphatase (ALP) data
and dynamically updated predicted probabilities of ITR to UDCA
treatment for four selected patients. a ALP measurements over time
for four sample patients. b Corresponding predicted probabilities and
95% confidence intervals for ITR for the same sample patients

C, estimated risk of high ITR was high at baseline (predicted probability > 99%). However, as ALP levels decreased
after 2 months, the predicted ITR risk also decreased; at
6 months, patient C’s estimated risk of ITR dropped to 0.06
(95% CI: -0.01–0.13). In contrast, despite a similar precipitous decline in ALP in the first two months after treatment,
patient D remained at high risk of ITR (≥ 95%) across the
first 6 months post-treatment initiation.
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In a large sample of PBC patients from eleven US health
systems, roughly half (45%) of UDCA-treated patients
demonstrated ITR. These real-world results are consistent
with rates of ITR (20–50%) observed in our own and other
studies.1 Accurate early identification of patients at greatest
risk of ITR may allow clinicians to optimize monitoring and
care. In response to the growing emphasis on personalized
medicine—the “right treatment for the right person at the
right time”10— we developed a personalized risk prediction
model that can predict ITR in a subgroup of patients with
high PPV and specificity within 4–6 months of treatment initiation, much sooner than the currently recommended observation time. Our model also showed that baseline values may
simply not be sufficient to identify all likely responders or
non-responders10. As shown in Fig. 3, both patients C and D
started with ALP levels that suggested a similar likelihood of
ITR; however, as data became available regarding the change
in ALP over time, their risk of ITR diverged. This enhanced
recognition of what essentially defines UDCA treatment
futility could lead to more timely identification of high-risk
patients; the excellent accuracy (AUROC = 0.91), PPV of
85% and near-perfect specificity (> 98%) should give clinicians confidence to explore additional treatment options for
the subset of patients identified as non-responders.
Given that there is no universally accepted method for
defining inadequate response to UDCA treatment, we evaluated both the m-URS and our dynamic model against two
of the most commonly used criteria. Our data showed that
27% of patients had ITR at 12 months from index using
ALP > 1.67*ULN, whereas 45% had ITR using Paris II criteria. Our own recent study7 showed that Paris II criteria are
an independent prognostic marker for mortality among PBC
patients regardless of UDCA treatment. Using data from our
racially diverse cohort, we assessed the m-URS (a version
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of the URS using baseline-only values) that was developed by the UK-PBC consortium using a European cohort.
Accuracy of the m-URS in our racially diverse cohort was
similar to that from the UK-PBC cohort (AUROC of 0.85,
95% CI 0.81–0.89) using ALP > 1.67*ULN to define ITR.
The UK-PBC group also evaluated three other cutoffs
(ALP > 1*ULN; ALP ≥ 1.5*ULN; and ALP ≥ 2*ULN);
using these cutoffs, AUROC was reduced to 0.81–0.82 (95%
CI 0.77–0.87). In light of this, we also assessed accuracy of
the m-URS using Paris II cutoffs; predictive ability was only
moderate (AUROC of 0.74).
An unavoidable limitation of any observational study is
missing data, especially data collected in a real-world setting. For the validation of m-URS, we addressed this concern by performing multiple imputation11; analysis was
performed on each imputed dataset, with each set of result
combined into a single final result. This method addresses
two common concerns regarding imputation of missing
data: 1) that imputation based on a regression prediction
may be too precise; 2) possible overestimation because
observed values are used for the imputation. Although our
model used parameters that should be readily available in
the medical record of PBC patients under routine care, it
is possible that values for some variables may be missing,
reducing its predictive ability in these cases. In the dynamic
risk prediction model, the parameter estimates were updated
monthly if additional laboratory data became available; if
no additional measurement was available, the slope derived
from the previous measure was used. An advantage of this
method is the flexibility with missing values and timing of
measurements, as the model can still be applied to irregular
measurement intervals, as commonly occurs in routine care
settings. The method is also designed to be conceptually
simple and practical for use by clinicians. Further sensitivity analysis using alternative imputation methods may be
needed to test the robustness of the model. However, as the
focus of this paper is to predict ITR rather than estimating
a treatment effect, assessing different imputation methods
is beyond the scope of this paper. Although our ability to
make comparisons is limited by the relatively small sample
size of our validation data, our predictive model does demonstrate significantly improved predictability of the dynamic
risk prediction model starting from 3 to 4 months post-treatment initiation using both AUROC and AUPRC metrics. A
larger validation study is needed to address ideal duration of
follow-up measures and appropriate cutoffs.
Using data from a single time point (time of treatment
initiation), the four-variable m-URS had “very good” predictive ability (AUROC 0.85–0.87) when validated against data
from our multi-racial US cohort; PPV and specificity were
roughly 80% and 60%, respectively. In contrast, our two-part
dynamic predictive model that used both the values and trajectory of laboratory markers measured over time during the

first seven months after treatment initiation reached “excellent” predictive ability (0.91), with very high PPV (85%)
and specificity (98%)—which indicates that those patients
identified by this model are unlikely to be misclassified as
non-responders. Such a model could address a central issue
pertaining to the current definition of UDCA response at
12 months post-treatment initiation—specifically, that those
patients who might benefit the most from combination and
second-line therapies must wait a year before such treatment
is initiated. The high specificity (98%) of our model means it
identifies only patients for whom UDCA treatment is futile.
For these patients, an additional six months wait before initiating second-line treatments may be unnecessarily burdensome, particularly given variation in insurance status and
volatility in generic UDCA pricing in the USA.
In conclusion, we used real-world data drawn from a
racially and geographically diverse cohort of PBC patients
in the USA to develop a dynamic prediction model for inadequate response to UDCA, which provided “excellent” predictive ability, as well as 98% specificity to identify patients
at the highest risk of ITR within 6 months of UDCA treatment initiation. This method may allow clinicians to use routine care data to identify earlier those patients deemed ITR
who will benefit from heightened monitoring and prompt
initiation of adjuvant and/or second-line therapies.
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